Webbwhich have been life-threatening and fatal, have been reported in patients receiving Injectafer. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Injectafer administration for at least 30 minutes WebbSee full prescribing information for Injectafer. INJECTAFER ® (ferric carboxymaltose injection), for intravenous use Initial U.S. Approval: 2013 -----INDICATIONS AND USAGE-----Injectafer is an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients:
Injectafer (ferric carboxymaltose) dosing, indications, interactions ...
WebbVenofer ® (iron sucrose) injection, USP is an established and effective treatment for chronic kidney disease (CKD) patients experiencing iron deficiency anemia (IDA). Venofer provides IV iron therapy for the treatment of IDA in adult and pediatric patients 2 years and older with CKD. The dosing for iron replacement treatment in pediatric ... jayenne therese manalo
label - Food and Drug Administration
WebbInjectafer ® (ferric carboxymaltose injection) is indicated for the treatment of iron deficiency anemia (IDA) in adult and pediatric patients 1 year of age and older who have either intolerance to oral iron or an unsatisfactory response to oral iron, or adult patients who have non-dialysis dependent chronic kidney disease. WebbRequired Billing and Coding J Code J Code Product Indications Injectafer® (ferric carboxymaltose injection) is an iron replacement product indicated for the treatment of IDA in adult patients: Injection, ferric • who have intolerance to or have had J1439 carboxymaltose, 1 mg unsatisfactory response to oral iron or • who have non-dialysis … WebbInjectafer ® (ferric carboxymaltose injection) is indicated for the treatment of iron deficiency anemia (IDA) in adult and pediatric patients 1 year of age and older who … jay enhyphen birthday